Geniposidic acid ameliorates spatial learning and memory deficits and alleviates neuroinflammation via inhibiting HMGB-1 and downregulating TLR4/2 signaling pathway in APP/PS1 mice.
Alzheimer Disease
/ drug therapy
Amyloid beta-Peptides
/ metabolism
Amyloid beta-Protein Precursor
/ genetics
Animals
Anti-Inflammatory Agents
/ pharmacology
Astrocytes
/ drug effects
Cerebral Cortex
/ drug effects
Cytokines
/ metabolism
Disease Models, Animal
Down-Regulation
Hippocampus
/ drug effects
Iridoid Glucosides
/ pharmacology
Memory
/ drug effects
Memory Disorders
/ drug therapy
Mice, Transgenic
Microglia
/ drug effects
Neuroprotective Agents
/ pharmacology
Presenilin-1
/ genetics
Signal Transduction
/ drug effects
Spatial Learning
/ drug effects
Toll-Like Receptor 2
/ genetics
Toll-Like Receptor 4
/ genetics
Alzheimer's disease
Amyloid-β peptide
Geniposidic acid
HMGB-1
Neuroinflammation
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
15 Feb 2020
15 Feb 2020
Historique:
received:
16
04
2019
revised:
26
11
2019
accepted:
09
12
2019
pubmed:
16
12
2019
medline:
21
10
2020
entrez:
16
12
2019
Statut:
ppublish
Résumé
Geniposidic acid (GPA) is an extract from Eucommia ulmoides Oliv. Bark (Eucommiaceae). Accumulating evidences have reported GPA has anti-aging, anti-oxidative stress, anti-inflammatory and neurotrophic effects on neurons. However, whether GPA could alleviate memory deficits in Alzheimer's disease animal models is not clear. We aimed to investigate the effect of GPA treatment on cognitive performance, Aβ deposition and glial cells activation in the transgenic mouse model of AD. 6-7 months APP/PS1 mice were given GPA for 90 days; behavioral experiments were executed to estimate the memory and spatial learning abilities of mice, and the mechanism of neuroprotective effect of GPA was investigated with a focus on amyloid-β deposition, astrocytes and microglia activation and neuroinflammation. GPA treatment significantly improved the spatial learning and memory abilities and also decreased cerebral amyloid-β deposition in APP/PS1 mice. Via HE staining, we found that GPA could ameliorate histopathological changes in cerebrum. We also found that GPA treatment inhibited the activation of astrocytes and microglia, down-regulated the expression of pro-inflammatory cytokines and iNOS, and up-regulated the expression of anti-inflammatory cytokines and Arg-1. In addition, GPA down-regulated the gene expression of HMGB-1 receptors (TLR2, TLR4 and RAGE) then mediated MyD88, TRAF6 and phospho-ERK1/2, subsequently modulated the expression of key AP-1 and NF-κB family members (c-Fos, c-Jun and p65). The reversal of the pro-inflammatory state suggested GPA can serves as a multi-target candidate by alleviating Aβ deposition and neuroinflammation for the auxiliary therapy of Alzheimer's disease.
Identifiants
pubmed: 31837991
pii: S0014-2999(19)30809-X
doi: 10.1016/j.ejphar.2019.172857
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Amyloid beta-Protein Precursor
0
Anti-Inflammatory Agents
0
Cytokines
0
Iridoid Glucosides
0
Neuroprotective Agents
0
Presenilin-1
0
Tlr2 protein, mouse
0
Tlr4 protein, mouse
0
Toll-Like Receptor 2
0
Toll-Like Receptor 4
0
geniposidic acid
27741-01-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172857Informations de copyright
Copyright © 2019. Published by Elsevier B.V.